XML 54 R41.htm IDEA: XBRL DOCUMENT v3.19.1
Summary of Significant Accounting Policies - Additional Information (Detail)
3 Months Ended 12 Months Ended
Dec. 31, 2018
USD ($)
Asset
$ / shares
Dec. 31, 2018
USD ($)
Segment
Asset
$ / shares
Dec. 31, 2017
USD ($)
Dec. 31, 2019
USD ($)
Oct. 10, 2018
$ / shares
Mar. 09, 2017
$ / shares
Dec. 31, 2016
USD ($)
Significant Accounting Policies [Line Items]              
Number of operating segments | Segment   1          
Carrying value of assets $ 38,872,537 $ 38,872,537 $ 39,209,211        
Goodwill impairment charges   490,676 35,919,695        
Fair value transfers, Level 1 to Level 2 assets     0       $ 0
Fair value transfers, Level 2 to Level 1 assets     0       0
Fair value transfers, Level 1 to Level 2 liabilities     0       0
Fair value transfers, Level 2 to Level 1 liabilities     0       0
Restricted cash $ 634,416 $ 634,416 $ 3,534,174        
Per share exercise price | $ / shares $ 5.03 $ 5.03       $ 0.01  
ASU 2016-02 [Member] | Scenario, Forecast [Member]              
Significant Accounting Policies [Line Items]              
Operating lease, right-of-use asset       $ 2,000,000      
Revenue from Rights Concentration Risk [Member] | Research Grants and Contracts [Member]              
Significant Accounting Policies [Line Items]              
Percentage of concentration of credit risk   100.00% 100.00%        
Revenue from Rights Concentration Risk [Member] | Accounts Receivable [Member]              
Significant Accounting Policies [Line Items]              
Percentage of concentration of credit risk   100.00% 100.00%        
Money Market Funds [Member]              
Significant Accounting Policies [Line Items]              
Restricted cash $ 634,416 $ 634,416          
IPR&D [Member]              
Significant Accounting Policies [Line Items]              
Number of assets | Asset 3 3          
Intangible assets, amount $ 13,418,967 $ 13,418,967 $ 38,245,871       $ 14,477,019
Carrying value of assets 22,389,000 22,389,000          
Impairment of intangible assets 21,389,000 24,450,011          
IPR&D [Member] | Oncosyn Cancer Immunotherapy [Member]              
Significant Accounting Policies [Line Items]              
Intangible assets, amount $ 3,061,011 $ 3,061,011          
IPR&D [Member] | HepTcell and SparVax-L [Member]              
Significant Accounting Policies [Line Items]              
Number of assets | Asset 2 2          
IPR&D [Member] | SparVax-L [Member]              
Significant Accounting Policies [Line Items]              
Fair value of intangible assets $ 1,000,000 $ 1,000,000          
Minimum [Member]              
Significant Accounting Policies [Line Items]              
Intangible assets amortization period   6 years          
Minimum [Member] | Second Registered Direct Offering [Member]              
Significant Accounting Policies [Line Items]              
Per share exercise price | $ / shares         $ 4.1798    
Maximum [Member]              
Significant Accounting Policies [Line Items]              
Intangible assets amortization period   20 years          
Maximum [Member] | Second Registered Direct Offering [Member]              
Significant Accounting Policies [Line Items]              
Per share exercise price | $ / shares         $ 6.00    
Maximum [Member] | IPR&D [Member] | HepTcell [Member]              
Significant Accounting Policies [Line Items]              
Percent of fair value of reporting unit excess of carrying value 10.00% 10.00%